Ngā hua rapu - Jamison B. Tuttle
- E whakaatu ana i te 1 - 4 hua o te 4
-
1
An inverse agonist of orphan receptor GPR61 acts by a G protein-competitive allosteric mechanism mā Joshua A. Lees, João M. Dias, Francis Rajamohan, Jean‐Philippe Fortin, Rebecca E. O’Connor, Jimmy X. Kong, Emily Hughes, Ethan L. Fisher, Jamison B. Tuttle, Gabrielle Lovett, Bethany L. Kormos, Rayomand J. Unwalla, Lei Zhang, Anne‐Marie Dechert Schmitt, Dahui Zhou, Michael Moran, Kimberly A. Stevens, Kimberly F. Fennell, Alison E. Varghese, Andrew Maxwell, Emmaline E. Cote, Yuan Zhang, Seungil Han
I whakaputaina 2023Artigo -
2
Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia mā Amy B. Dounay, Marie Anderson, Bruce M. Bechle, Brian Campbell, Michelle M. Claffey, A.G. Evdokimov, Edelweiss Evrard, Kari R. Fonseca, Xinmin Gan, Somraj Ghosh, Matthew M. Hayward, W. Elliott Horner, Jiyoung Kim, Laura A. McAllister, Jayvardhan Pandit, Vanessa Paradis, Vinod D. Parikh, Matthew R. Reese, Suo‐Bao Rong, Michelle A. Salafia, Katherine Schuyten, Christine A. Strick, Jamison B. Tuttle, James J. Valentine, Hong Wang, Laura E. Zawadzke, Patrick R. Verhoest
I whakaputaina 2012Artigo -
3
An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19 mā Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson, Lisa Aschenbrenner, Melissa Avery, Simon Berritt, Britton Boras, Rhonda D. Cardin, Anthony Carlo, Karen J. Coffman, Alyssa Dantonio, Li Di, Heather Eng, Rose Ann Ferre, K.S. Gajiwala, Scott Gibson, S.E. Greasley, Brett L. Hurst, Eugene P. Kadar, Amit S. Kalgutkar, Jack C. Lee, Jisun Lee, Wei Liu, Stephen W. Mason, Stephen Noell, Jonathan J. Novak, R. Scott Obach, Kevin Ogilvie, Nandini C. Patel, Martin Pettersson, K. Devendra, Matthew R. Reese, M. F. Sammons, Jean G. Sathish, Ravi Shankar Prasad Singh, Claire M. Steppan, Al Stewart, Jamison B. Tuttle, Lawrence W. Updyke, Patrick R. Verhoest, Liuqing Wei, Qingyi Yang, Yuao Zhu
I whakaputaina 2021Artigo -
4
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19 mā Charlotte Allerton, Joel T. Arcari, Lisa Aschenbrenner, Melissa Avery, Bruce M. Bechle, Mohammad Amin Behzadi, Britton Boras, Leanne M. Buzon, Rhonda D. Cardin, Natasha R. Catlin, Anthony Carlo, Karen J. Coffman, Alyssa Dantonio, Li Di, Heather Eng, Kathleen A. Farley, Rose Ann Ferre, Steven Gernhardt, Scott Gibson, S.E. Greasley, Siennah R. Greenfield, Brett L. Hurst, Amit S. Kalgutkar, Emi Kimoto, Lorraine F. Lanyon, Gabrielle H. Lovett, Yajing Lian, Wei Liu, Luis Martinez-Alsina, Stephen Noell, R. Scott Obach, Dafydd R. Owen, Nandini C. Patel, K. Devendra, Matthew R. Reese, Hussin A. Rothan, Sylvie K. Sakata, M. F. Sammons, Jean G. Sathish, Raman Sharma, Claire M. Steppan, Jamison B. Tuttle, Patrick R. Verhoest, Liuqing Wei, Qingyi Yang, Irina Yurgelonis, Yuao Zhu
I whakaputaina 2024Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Biochemistry
Chemistry
Medicine
Pharmacology
Antiretroviral therapy
Biology
Coronavirus disease 2019 (COVID-19)
Disease
Enzyme
Infectious disease (medical specialty)
Internal medicine
Outbreak
Protease inhibitor (pharmacology)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Viral load
Virology
Virus
2019-20 coronavirus outbreak
Active site
Agonist
Allosteric modulator
Allosteric regulation
Amino acid
Biotechnology
Clinical trial
Computational biology
Coronavirus
Coronavirus Infections
Drug discovery
Druggability